{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:02:12Z","timestamp":1772118132246,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness and tolerability of agomelatine with mirtazapine in patients with depressive disorder. To illustrate the prescribing pattern of agomelatine and identify factors that affect the pattern of treatment result and therapeutic outcome of it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data of patients using agomelatine or mirtazapine, 93 patients in each group, were included and reviewed in this retrospective study. Background characteristics, adverse events, therapeutic outcomes (discontinued or continued), reason of discontinuation, and the presence of positive pattern of treatment result were assessed. Positive pattern of treatment result was defined as either recovery or improvement of depressive disorder after therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients using agomelatine were associated with higher starting dose and higher dose titrated than mirtazapine. More patients started agomelatine due to intolerability, and less due to ineffectiveness of the previous antidepressant. More patients started agomelatine before the use of at least two selective serotonin reuptake inhibitor (SSRI)\/serotonin\u2010noradrenaline reuptake inhibitor (SNRI). Patients using agomelatine were associated with less discontinuation due to intolerability, and less experience of adverse events within 90 days of initiation or dose increase, but more discontinuation due to ineffectiveness versus mirtazapine. The use of 50\u00a0mg resulted in less discontinuation. The use of at least two SSRI(s)\/SNRI(s) before and more concomitant medications are independently associated with more discontinuation due to intolerability. The use of at least two SSRI(s)\/SNRI(s) before was also associated with more adverse events. Using agomelatine as an augmentation to other antidepressant(s) and at a higher dose were independently associated with the experience of positive pattern of treatment result.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Agomelatine was more tolerable than mirtazapine, but could result in more discontinuation due to ineffectiveness. The use of higher dose and as an augmentation to other antidepressant(s) could improve the desired treatment result of agomelatine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.2311","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T13:57:20Z","timestamp":1627826240000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug use evaluation: A two\u2010year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3102-9992","authenticated-orcid":false,"given":"Shek Ming","family":"Leung","sequence":"first","affiliation":[{"name":"Institute of Vocational Education \u2010 Kwai Chung Campus  New Territory Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Allergan. (2017a).Lexapro: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021323s047lbl.pdf"},{"key":"e_1_2_9_3_1","unstructured":"Allergan. (2017b).Celexa [package insert].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020822s047lbl.pdf"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/25.6.666"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.16407"},{"key":"e_1_2_9_7_1","unstructured":"Eli Lilly and Company. (2010).Cymbalta: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022516lbl.pdf"},{"key":"e_1_2_9_8_1","unstructured":"Eli Lilly and Company. (2017).Prozac: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018936s108lbl.pdf"},{"key":"e_1_2_9_9_1","unstructured":"Emc. (2018a).Trazodone 50 mg Capsules.https:\/\/www.medicines.org.uk\/emc\/product\/7186\/smpc"},{"key":"e_1_2_9_10_1","unstructured":"Emc. (2018b).Brintellix tablets 5 10 and 20 mg.https:\/\/www.medicines.org.uk\/emc\/product\/7121\/smpc"},{"key":"e_1_2_9_11_1","unstructured":"Emc. (2020a).Clomipramine 10 mg capsules hard.https:\/\/www.medicines.org.uk\/emc\/product\/2552\/smpc"},{"key":"e_1_2_9_12_1","unstructured":"Emc. (2020b).Citalopram 20 mg tablets.https:\/\/www.medicines.org.uk\/emc\/product\/5737\/smpc"},{"key":"e_1_2_9_13_1","unstructured":"Emc. (2021).Escitalopram 20 mg tablets.https:\/\/www.medicines.org.uk\/emc\/product\/7059\/smpc#gref"},{"key":"e_1_2_9_14_1","unstructured":"Excellium Pharmaceutical Inc. (2012).Imipramine: Prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/040903lbl.pdf"},{"key":"e_1_2_9_15_1","first-page":"36","article-title":"Mirtazapine: Other indications","volume":"60","author":"Falkai P.","year":"1999","journal-title":"The Journal of Clinical Psychiatry"},{"key":"e_1_2_9_16_1","unstructured":"GlaxoSmithKline. (2009).Wellbutrin XL: Prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021515s023s024lbl.pdf"},{"key":"e_1_2_9_17_1","unstructured":"GlaxoSmithKline. (2012).Paxil: Prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020031s067 020710s031.pdf"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.554534"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008851.pub2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(11)60095\u20100"},{"key":"e_1_2_9_21_1","unstructured":"Jazz Pharmaceuticals. (2008).Luvox: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022235lbl.pdf"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05347blu"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300341"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172b48c"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534420\u2010000000000\u201000000"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1112"},{"key":"e_1_2_9_27_1","unstructured":"Mallinckrodt Inc. (2007a).Anafranil [package insert].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/019906s34lbl.pdf"},{"key":"e_1_2_9_28_1","unstructured":"Mallinckrodt Inc. (2007b).Pamelor [package insert].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/018013s58lbl.pdf"},{"key":"e_1_2_9_29_1","unstructured":"Mylan. (2013).Mianserin: Package leaflet: Information for the patient.https:\/\/www.medicines.org.uk\/emc\/files\/pil.2741.pdf"},{"key":"e_1_2_9_30_1","unstructured":"Mylan. (2019).Dothep: Australian product information.https:\/\/apps.medicines.org.au\/files\/afpdothe.pdf"},{"key":"e_1_2_9_31_1","unstructured":"NHS. (2018).Dosulepin deprescribing guidance.https:\/\/www.tewv.nhs.uk\/content\/uploads\/2018\/09\/Dosulepin\u2010guidance.pdf"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2018.02.017"},{"key":"e_1_2_9_33_1","unstructured":"Pfizer. (2011).Pristiq: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021992s030lbl.pdf"},{"key":"e_1_2_9_34_1","unstructured":"Pfizer. (2016).Zoloft: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839S74S86S87_20990S35S44S45lbl.pdf"},{"key":"e_1_2_9_35_1","unstructured":"Pfizer. (2017).Effexor XR: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020699s107lbl.pdf"},{"key":"e_1_2_9_36_1","unstructured":"Pragma Pharmaceuticals LLC. (2017).Desyrel: Highlights of prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018207s032lbl.pdf"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328349b117"},{"key":"e_1_2_9_38_1","unstructured":"Sandoz. (2014).Amitriptyline Hydrochloride [package insert].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/085966s095 085969s084 085968s096 085971s075 085967s076 085970s072lbl.pdf"},{"issue":"11","key":"e_1_2_9_39_1","first-page":"9","article-title":"New indications for antidepressants","volume":"61","author":"Schatzberg A. F.","year":"2000","journal-title":"The Journal of Clinical Psychiatry"},{"key":"e_1_2_9_40_1","unstructured":"Schering Corporation(2009). Remeron [package insert].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020415s023s024.pdf. Accessed April 24 2021."},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a5233f"},{"key":"e_1_2_9_42_1","unstructured":"Servier. (2018).Valdoxan: Summary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/valdoxan\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199856030\u201000010"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0924\u2010977X(93)90264\u2010M"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318184ff5b"},{"key":"e_1_2_9_46_1","unstructured":"Takeda Pharmaceuticals America Inc. (2014).Brintellix: Medication guide.https:\/\/www.fda.gov\/media\/86743\/download"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1888"},{"key":"e_1_2_9_48_1","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor D.","year":"2015"},{"key":"e_1_2_9_49_1","unstructured":"Teva Select Brands. (2014).Surmontil [package insert].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/016792s037lbl.pdf"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100447.1998.tb09980.x"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006057600400208"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006\u20103223(00)00882\u20109"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/brb3.2311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T23:46:39Z","timestamp":1692315999000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.2311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/brb3.2311"],"URL":"https:\/\/doi.org\/10.1002\/brb3.2311","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.2311\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2311\/v2\/decision1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2021-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2311"}}